Ask AI
ProCE Banner Activity

VOLITION Primary Analysis: Phase III Trial of Early LA CAB + RPV Switch After Achieving Virologic Suppression With DTG/3TC in Treatment-Naive Adults With HIV

Conference Coverage
Slideset

In primary analysis, among treatment-naive people with HIV, providing the option to switch to long-acting cabotegravir + rilpivirine immediately after achieving virologic suppression with dolutegravir/lamivudine was highly efficacious and preferred at 11 months.

Released: February 27, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This program is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions